Kidneys play a vital role in regulating blood volume and excreting toxins and drugs. On the other hand, the fact that the kidneys are highly absorbent makes them vulnerable to toxicity and injury. Cyclophosphamide (CTX) is an effective anti-tumor agent for different types of tumors and an immunosuppressive agent for organ transplantation and autoimmune diseases. Despite its effectiveness, the use of CTX is associated with urotoxicity and nephrotoxicity, which are major limitations of CTX-based chemotherapy.
Pyrroloquinoline quinone (PQQ) is a new type of water-soluble anionic redox compound within anti-oxidative, anti-inflammatory, hepatoprotective, neuroprotective, antiosteoporotic, and other biological activities. Until now, there have been no reports on the use of PQQ against CTX-induced nephrotoxicity. Our results suggest that PurePQQ® has a potential protective effect against CTX-induced nephrotoxicity. PurePQQ® exhibited anti-oxidative and anti-inflammatory properties in the kidney of CTX-induced mice via upregulating the Nrf2/HO-1 signaling pathway and inhibiting the NLRP3 inflammatory pathway (Fig. 2), suggesting that PurePQQ® has the potential to ameliorate CTX-induced nephrotoxicity.
PurePQQ® is developed and produced with ECA’s proprietary technology under the cGMP facility and is ideally suitable for use in dietary supplements and functional medical foods.
Data from: Ameliorate effect of pyrroloquinoline quinone against cyclophosphamide-induced nephrotoxicity by activating the Nrf2 pathway and inhibiting the NLRP3 pathway.
Life Sciences, 2020, 256: 117901. https://doi.org/10.1016/j.lfs.2020.117901.
